Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca to cut 8,000 jobs

Anglo-Swedish pharmaceutical giant, AstraZeneca is to cut 8,000 jobs worldwide by 2014

Anglo-Swedish pharmaceutical giant, AstraZeneca (AZ) has announced it is to cut 8,000 jobs worldwide by 2014.

AZ, which employs 11,000 people in the UK, including offices in London, Macclesfield, Cheshire, Luton and Bristol, has yet to say how the job cuts will affect the UK.

The cuts come on top of 12,600 job losses since 2007 as the firm continues to further its 'productivity programmes' which have already saved $1.6bn. AZ has predicted a further $1.8bn to be saved over the next four years with this latest announcement.

The losses will come in the firm's sales and marketing, business infrastructure, research and development, and supply chain operations, as AZ looks to focus on its more profitable drugs and treatment departments.

There was also a warning that some research and development sites could be closed.

The news comes as AZ announced a "strong financial performance in 2009" which saw the firm's annual revenues increase by seven per cent, as well as the elimination of its $7,174m net debt.

28th January 2010

Share

Subscribe to our email news alerts

PMHub

Add my company
Page & Page and Partners

Page & Page is an independent creative agency on a mission to close the healthcare gap through the power of...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...